E
Eileen M. Barry
Researcher at University of Maryland, Baltimore
Publications - 94
Citations - 3113
Eileen M. Barry is an academic researcher from University of Maryland, Baltimore. The author has contributed to research in topics: Enterotoxigenic Escherichia coli & Francisella tularensis. The author has an hindex of 31, co-authored 91 publications receiving 2706 citations. Previous affiliations of Eileen M. Barry include University of Maryland, College Park.
Papers
More filters
Journal ArticleDOI
Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road
TL;DR: The most advanced strategies for Shigella vaccine development, the immune responses that are elicited following disease or vaccination, the factors that have accelerated or impeded Shigellosis vaccine development and the ideas for the way forward are discussed.
Journal ArticleDOI
Shigella Isolates From the Global Enteric Multicenter Study Inform Vaccine Development
Sofie Livio,Nancy Strockbine,Sandra Panchalingam,Sharon M. Tennant,Eileen M. Barry,Mark E. Marohn,Martin Antonio,Anowar Hossain,Inacio Mandomando,John B. Ochieng,Joseph Oundo,Shahida Qureshi,Thandavarayan Ramamurthy,Boubou Tamboura,Richard A. Adegbola,Mohammed Jahangir Hossain,Debasish Saha,Sunil Sen,Abu Syed Golam Faruque,Pedro L. Alonso,Robert F. Breiman,Anita K. M. Zaidi,Dipika Sur,Samba O. Sow,Lynette Y. Berkeley,Ciara E. O’Reilly,Eric D. Mintz,Kousick Biswas,Dani Cohen,Tamer H. Farag,Dilruba Nasrin,Yukun Wu,William C. Blackwelder,Karen L. Kotloff,James P. Nataro,Myron M. Levine +35 more
TL;DR: A quadrivalent vaccine that includes O antigens from S. sonnei, S. flexneri, and S.flexneri 6 should provide broad protection in Shigella case isolates.
Journal ArticleDOI
Progress and pitfalls in Shigella vaccine research.
Eileen M. Barry,Marcela F. Pasetti,Marcelo B. Sztein,Alessio Fasano,Karen L. Kotloff,Myron M. Levine +5 more
TL;DR: The latest progress in Shigella vaccine development is reviewed within the framework of persistent obstacles, lending promise to the potential for production of safe and effective ShIGella vaccines.
Journal ArticleDOI
Toll-Like Receptor 2-Mediated Signaling Requirements for Francisella tularensis Live Vaccine Strain Infection of Murine Macrophages
Leah E. Cole,Kari Ann Shirey,Eileen M. Barry,Araceli E. Santiago,Prasad Rallabhandi,Karen L. Elkins,Adam C. Puche,Suzanne M. Michalek,Stefanie N. Vogel +8 more
TL;DR: It is reported that F. tularensis LVS-induced murine macrophage proinflammatory cytokine gene and protein expression are overwhelmingly TLR2 dependent, as evidenced by the abrogated responses ofTLR2−/− macrophages.
Journal ArticleDOI
Attenuated Salmonella as live oral vaccines against typhoid fever and as live vectors
Myron M. Levine,James E. Galen,Eileen M. Barry,Fernando R. Noriega,Steven N. Chatfield,Marcelo B. Sztein,Gordon Dougan,Carol O. Tacket +7 more
TL;DR: Both CVD 908 and CVD908-htrA are useful as live vector vaccines to deliver foreign antigens to the immune system and conditions that enhance the expression and immunogenicity of foreign antIGens carried by CVD 788 and 908 are being investigated.